ReviewJournal of inflammation research2026
Targeting the Gut Microbiota with Herbal Compounds from Traditional Chinese Medicine: A Mechanistic Synthesis of a Novel Therapeutic Approach for Ulcerative Colitis.
Review in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis (UC) represents a chronic relapsing inflammatory bowel disease characterized by substantial unmet clinical needs and limited curative modalities. Accumulating evidence implicates gut microbiota dysbiosis as a pivotal pathogenic driver, positioning microbiota-targeted interventions as promising therapeutic strategies. This review systematically delineates the mechanisms by which herbal compounds from Traditional Chinese Medicine ameliorate UC through the restoration of microbial and metabolic homeostasis-including the modulation of beneficial commensals and their bioactive metabolites-thereby reinforcing intestinal barrier integrity and dampening mucosal inflammation. Although translational bottlenecks persist, integrative multi-omics frameworks coupled with advanced pharmaceutical engineering offer viable pathways to bridge preclinical findings and clinical application. Taken together, deciphering the bidirectional crosstalk between herbal compounds and the gut microbiome paves the way for mechanism-based, personalized botanical therapeutics in UC management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.